Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Egg Consumption on Cardiometabolic Health in Prediabetic Subjects.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03332927
Recruitment Status : Completed
First Posted : November 6, 2017
Last Update Posted : July 24, 2019
Sponsor:
Information provided by (Responsible Party):
Midwest Center for Metabolic and Cardiovascular Research

Brief Summary:
The objective of this trial is to assess the effects of whole egg consumption (12 per week), compared to energy-matched typical breakfast control foods, on insulin sensitivity and other markers of metabolic health, including fasting lipoprotein lipid levels and resting blood pressure.

Condition or disease Intervention/treatment Phase
PreDiabetes Other: Egg based breakfast foods Other: Non-egg based breakfast foods Not Applicable

Detailed Description:

This is a randomized, crossover study that includes two screening visits and two 4-week test periods separated by a 4-week washout. Subjects will consume two eggs/day (12 eggs/week consumed over 6 days per week, provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet) or non-egg based control foods (provided as breakfast foods such as English muffins, bagels, ready-to-eat cereal, and flavored muffins). The background diet will be a habitual diet. The nutritional profiles of the egg and control breakfast foods will be designed such that the energy from eggs will be substituted for a mixture of carbohydrate, protein and fat in the control foods.

Study foods will be dispensed with instructions to consume the assigned breakfast food starting on day 1. Subjects will be instructed to consume the breakfast foods in their entirety each day, for the duration of the 28 day test period, and to record daily study food intake. Subjects will receive diet instruction on the incorporation of food substitutions during the test period to maintain habitual energy intake. Compliance will be assessed using the Daily Log intake and number of foods consumed based on returned foods.

An intravenous glucose tolerance test (IVGTT) will be completed at baseline and the end of each treatment period for evaluation of insulin sensitivity. Blood will be collected for a fasting lipid profile (at all visits), glucose and insulin, high-sensitivity C-reactive protein (hs-CRP), vertical auto profile (VAP) for cholesterol carried by lipoprotein fractions (at baseline and end of each treatment period), with additional blood samples collected for storage and archived for possible future analysis of non-genetic indicators of metabolism. Assessments of vital signs and body weight, review of concomitant medication/supplement use and inclusion and exclusion criteria for relevant changes, and evaluation of adverse effects will be performed throughout the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Randomized, Crossover Trial to Assess the Effects of Replacing Commonly Consumed Breakfast Foods With Eggs on Insulin Sensitivity and Other Markers of Cardiometabolic Health in Men and Women at Increased Risk for Type 2 Diabetes Mellitus.
Actual Study Start Date : October 25, 2017
Actual Primary Completion Date : August 15, 2018
Actual Study Completion Date : August 15, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prediabetes

Arm Intervention/treatment
Experimental: Egg based breakfast foods
Study products delivering two eggs/day, 6 days per week, will be administered for the 4-week treatment period.
Other: Egg based breakfast foods
Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.

Active Comparator: Non-egg based breakfast foods
Study products delivering non-egg based control breakfast foods will be administered 6 days per week for the 4-week treatment period.
Other: Non-egg based breakfast foods
Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.




Primary Outcome Measures :
  1. Insulin sensitivity index (IV-SI) from short (40 min) IVGTT. [ Time Frame: Up to 40 minutes - measured at baseline and end of each treatment period. ]
    Percent change or change from baseline to end of each treatment condition


Secondary Outcome Measures :
  1. Disposition index [acute insulin response to intravenous glucose (AIRg) x IV-SI] [ Time Frame: Up to 40 minutes - measured at baseline and end of each treatment period. ]
    Percent change (or change) from baseline to the end of each treatment period.

  2. Glucose fractional disappearance rate from t = 10-40 min (Kg) [ Time Frame: Up to 40 minutes - measured at baseline and end of each treatment period. ]
    Percent change (or change) from baseline to the end of each treatment period.

  3. Homeostasis model assessments of insulin sensitivity (HOMA%S) [ Time Frame: Up to 29 days for each treatment period ]
    Percent change (or change) from baseline to the end of each treatment period.

  4. Beta-cell function (HOMA%B) [ Time Frame: Up to 29 days for each treatment period ]
    Percent change (or change) from baseline to the end of each treatment period.

  5. Percent change in Total cholesterol (TC) [ Time Frame: Up to 29 days for each treatment period ]
    Percent change in TC from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 3-week and 4-week visits of each test period)

  6. Percent change in low-density lipoprotein cholesterol (LDL-C) [ Time Frame: Up to 29 days for each treatment period ]
    Percent change in LDL-C from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 3-week and 4-week visits of each test period)

  7. Percent change in high-density lipoprotein cholesterol (HDL-C) [ Time Frame: Up to 29 days for each treatment period ]
    Percent change in HDL-C from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 3-week and 4-week visits of each test period)

  8. Percent change in non-HDL-C [ Time Frame: Up to 29 days for each treatment period ]
    Percent change in non-HDL-C from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 3-week and 4-week visits of each test period)

  9. Percent change in TC/HDL-C ratio [ Time Frame: Up to 29 days for each treatment period ]
    Percent change in TC/HDL-C ratio from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 3-week and 4-week visits of each test period)

  10. Percent change in Triglycerides (TG) [ Time Frame: Up to 29 days for each treatment period ]
    Percent change in TG from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 3-week and 4-week visits of each test period)

  11. Seated, resting systolic and diastolic blood pressure (BP) [ Time Frame: Up to 29 days for each treatment period ]
    Percent change in seated, resting systolic and diastolic BP (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 3-week and 4-week visits of each test period)

  12. Vertical Auto-Profile (VAP) analysis of cholesterol carried by lipoproteins and lipoprotein subfractions. [ Time Frame: Up to 29 days for each treatment period ]
    Percent change in VAP analysed cholesterol in lipoproteins and lipoprotein subfractions from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 3-week and 4-week visits of each test period)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. BMI of ≥25.0 kg/m2 (≥23.0 kg/m2 in Asian Americans) to 39.99 kg/m2.
  2. Metabolic syndrome [exhibiting at least 3 out of 5 of these criteria]: waist circumference ≥102 cm (40 inches) in men or ≥88 cm (35 inches) in women, TG level ≥150 mg/dL, HDL-C level <40 mg/dL in men or <50 mg/dL in women, hypertension: ≥130 systolic and/or /≥85 diastolic or on drug therapy for elevated BP, fasting hyperglycemia: 100-125 mg/dL.
  3. Prediabetes [exhibiting any of the criteria below at screening]: glycated hemoglobin 5.7-6.4% (inclusive), or fasting capillary glucose of 100-125 mg/dL (inclusive), or a 2-h postprandial glucose of 140-199 mg/dL.

Exclusion Criteria:

  1. Atherosclerotic cardiovascular disease including any of the following:

    clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., myocardial infarction, angina, transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound] or other forms of clinical atherosclerotic disease (e.g., renal artery disease).

  2. History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type 1 or 2 diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, neurologic, or biliary disorders.
  3. Known allergy, sensitivity, or intolerance to any ingredients in the study foods.
  4. Uncontrolled hypertension
  5. Recent history of cancer in the prior 5 years, except for non-melanoma skin cancer.
  6. Recent change in body weight of ±4.5 kg.
  7. Unstable use of any antihypertensive medication.
  8. Recent use of any medications intended to alter the lipid profile [e.g. bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, and/or proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors], weight-loss drugs, systemic corticosteroid drugs, medications known to influence carbohydrate (CHO) metabolism [e.g. adrenergic receptor blockers, thiazide diuretics, hypoglycemic medications], and/or anti-psychotics.
  9. Recent use of foods or dietary supplements that might influence lipid metabolism [e.g. omega-3 fatty acid supplements (e.g., fish or algal oils) or fortified foods, sterol/stanol products; dietary supplements (red rice yeast supplements; garlic supplements; soy isoflavone supplements; niacin or its analogues at doses >400 mg/d], inconsistent use of Metamucil® or viscous fiber-containing supplements
  10. Use of antibiotics within 5 days of screening.
  11. Pregnant, planning to be pregnant during the study period, lactating, or of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.
  12. Extreme dietary habits (e.g., vegan or very low carbohydrate diet).
  13. Current or recent history or strong potential, for drug or alcohol abuse.
  14. History of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa).
  15. Recent exposure to any non-registered drug product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03332927


Locations
Layout table for location information
United States, Illinois
Great Lakes Clinical Trials
Chicago, Illinois, United States, 60640
Sponsors and Collaborators
Midwest Center for Metabolic and Cardiovascular Research

Layout table for additonal information
Responsible Party: Midwest Center for Metabolic and Cardiovascular Research
ClinicalTrials.gov Identifier: NCT03332927     History of Changes
Other Study ID Numbers: MB-1704
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: July 24, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prediabetic State
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases